Literature DB >> 33170591

In-Hospital Management and Outcomes of Acute Myocardial Infarction Before and During the Coronavirus Disease 2019 Pandemic.

Bing Huang1, Changwu Xu, Huafen Liu, Wei Deng, Zheng Yang, Jun Wan, Hui Yan, Guiqiu Cao, Jing Chen, Hong Jiang.   

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread worldwide. This study sought to share our experiences with in-hospital management and outcomes of acute myocardial infarction (AMI) during the COVID-19 pandemic. We retrospectively analyzed consecutive AMI patients, including those with ST-elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI), from February 1, 2020, to April 15, 2020 (during the COVID-19 pandemic), and from January 1, 2019, to December 31, 2019 (before the COVID-19 pandemic), respectively. Fifty-three AMI patients (31 STEMI, 22 NSTEMI) during the COVID-19 pandemic were matched to 53 AMI patients before the pandemic. Baseline characteristics were comparable between the matched patients. STEMI patients during the COVID-19 pandemic had a longer delay time, less primary or remedial PCI and more emergency thrombolysis than those before the pandemic. Less coronary angiography and stenting were performed in AMI patients during the COVID-19 pandemic than before the pandemic. There were no statistically significant differences in the clinical outcomes between the matched patients. However, STEMI patients during the COVID-19 pandemic had a 4-fold (12.9% vs. 3.2%) increase in all-cause mortality rate compared with those before the pandemic. AMI combined with COVID-19 infection was associated with higher rates of mortality than AMI alone. This study demonstrates that the COVID-19 pandemic results in significant reperfusion delays in STEMI patients and has a marked impact on the treatment options selection in AMI patients. The mortality rate of STEMI patients exhibits an increasing trend during the pandemic of COVID-19.

Entities:  

Mesh:

Year:  2020        PMID: 33170591     DOI: 10.1097/FJC.0000000000000909

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Non-COVID outcomes associated with the coronavirus disease-2019 (COVID-19) pandemic effects study (COPES): A systematic review and meta-analysis.

Authors:  Vincent Issac Lau; Sumeet Dhanoa; Harleen Cheema; Kimberley Lewis; Patrick Geeraert; David Lu; Benjamin Merrick; Aaron Vander Leek; Meghan Sebastianski; Brittany Kula; Dipayan Chaudhuri; Arnav Agarwal; Daniel J Niven; Kirsten M Fiest; Henry T Stelfox; Danny J Zuege; Oleksa G Rewa; Sean M Bagshaw
Journal:  PLoS One       Date:  2022-06-24       Impact factor: 3.752

Review 2.  The Spill-Over Impact of the Novel Coronavirus-19 Pandemic on Medical Care and Disease Outcomes in Non-communicable Diseases: A Narrative Review.

Authors:  Ivy Lynn Mak; Eric Yuk Fai Wan; Teenie Kwan Tung Wong; Wendy Woo Jung Lee; Esther Wai Yin Chan; Edmond Pui Hang Choi; Celine Sze Ling Chui; Mary Sau Man Ip; Wallace Chak Sing Lau; Kui Kai Lau; Shing Fung Lee; Ian Chi Kei Wong; Esther Yee Tak Yu; Cindy Lo Kuen Lam
Journal:  Public Health Rev       Date:  2022-04-27

3.  Characteristics and outcomes of patients presenting with acute myocardial infarction and cardiogenic shock during COVID-19.

Authors:  Michael J Ahlers; Pratyaksh K Srivastava; Mir B Basir; William W O'Neill; Michael Hacala; Kareem Ammar; Suzan Khalil; John Hollowed; Ali Nsair
Journal:  Catheter Cardiovasc Interv       Date:  2022-09-07       Impact factor: 2.585

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.